Crinetics Pharmaceuticals Valuation Multiples

Crinetics Pharmaceuticals Overview

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Founded

2008

HQ

Employees

437

Website

crinetics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $23M

EBITDA: ($476M)

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Crinetics Pharmaceuticals Financials

Crinetics Pharmaceuticals reported last 12-month revenue of $23M and negative EBITDA of ($476M).

In the same LTM period, Crinetics Pharmaceuticals generated $21M in gross profit, ($476M) in EBITDA losses, and had net loss of ($473M).

Crinetics Pharmaceuticals P&L

In the most recent fiscal year, Crinetics Pharmaceuticals reported revenue of $8M and EBITDA of ($467M).

Crinetics Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Crinetics Pharmaceuticals Stock Performance

Crinetics Pharmaceuticals has current market cap of $4B, and enterprise value of $3B.

Crinetics Pharmaceuticals' stock price is $39.65.

Crinetics Pharmaceuticals Valuation Multiples

Crinetics Pharmaceuticals trades at 140.8x EV/Revenue multiple, and (6.7x) EV/EBITDA.

Crinetics Pharmaceuticals Financial Valuation Multiples

As of April 11, 2026, Crinetics Pharmaceuticals has market cap of $4B and EV of $3B.

Equity research analysts estimate Crinetics Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Crinetics Pharmaceuticals has a P/E ratio of (8.8x).

Crinetics Pharmaceuticals Margins & Growth Rates

Crinetics Pharmaceuticals' revenue in the last 12 month grew by 313%.

Crinetics Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.

Crinetics Pharmaceuticals' rule of 40 is (106%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Crinetics Pharmaceuticals' rule of X is 950% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Crinetics Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Crinetics Pharmaceuticals M&A Activity

Crinetics Pharmaceuticals acquired XXX companies to date.

Last acquisition by Crinetics Pharmaceuticals was on XXXXXXXX, XXXXX. Crinetics Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Crinetics Pharmaceuticals Investment Activity

Crinetics Pharmaceuticals invested in XXX companies to date.

Crinetics Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Crinetics Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).